FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2538-2541 June 14, 2007 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Zheng, Z. PubMed Citation

To the Editor: Zheng et al. (Feb. 22 issue)¹ conclude that the excision repair cross-complementation group 1 (ERCC1) protein is a determinant of survival after surgical treatment of early-stage non–small-cell lung cancer. The ERCC1 protein associates with the xeroderma pigmentosum group F (XPF) protein to form a nuclease that functions in DNA repair.² The level of ERCC1 protein was proposed as a useful predictor of response to cisplatin-based chemotherapy and clinical outcome,³ on the basis of immunohistochemical staining of tumors with the use of the monoclonal antibody 8F1. To our knowledge, however, no controlled experiments demonstrating the specificity of this . . . [Full Text of this Article]

This article has been cited by other articles:

• Olaussen, K. A., Fouret, P., Kroemer, G. (2007). ERCC1-Specific Immunostaining in Non-Small-Cell Lung Cancer. NEJM 357: 1559-1561 [Full Text]